Beauvericin (Standard)

[1]Mallebrera B, et al. In vitro mechanisms of Beauvericin toxicity: A review[J]. Food and Chemical Toxicology, 2018, 111: 537-545.|[2]Wang Q, et al. Beauvericin, a bioactive compound produced by fungi: a short review[J]. Molecules, 2012, 17 (3) : 2367-2377.|[3]Heilos D, et al. The natural fungal metabolite beauvericin exerts anticancer activity in vivo: a pre-clinical pilot study[J]. Toxins, 2017, 9 (9) : 258.|[4]Maranghi F, et al. In vivo toxicity and genotoxicity of beauvericin and enniatins. Combined approach to study in vivo toxicity and genotoxicity of mycotoxins beauvericin (BEA) and enniatin B (ENNB) [J]. EFSA Supporting Publications, 2018, 15 (5) : 1406E.|[5]Wang G, et al. Beauvericin exerts an anti-tumor effect on hepatocellular carcinoma by inducing PI3K/AKT-mediated apoptosis[J]. Archives of Biochemistry and Biophysics, 2023, 745: 109720.|[6]Dombrink-Kurtzman M A. Fumonisin and beauvericin induce apoptosis in turkey peripheral blood lymphocytes[J]. Mycopathologia, 2003, 156: 357-364.|[7]Wu S N, et al. Block of L-type Ca2+ current by beauvericin, a toxic cyclopeptide, in the NG108-15 neuronal cell line[J]. Chemical research in toxicology, 2002, 15 (6) : 854-860.|[8]Ficheux A S, et al. Effects of beauvericin, enniatin b and moniliformin on human dendritic cells and macrophages: An in vitro study[J]. Toxicon, 2013, 71: 1-10.|[9]Mei L, et al. An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats[J]. Journal of enzyme inhibition and medicinal chemistry, 2009, 24 (3) : 753-762.